ASX News

Telix Completes Licence Agreement with German Cancer Research Center (DKFZ) for Image-Guided Prostate Surgery

Melbourne (Australia) and Heidelberg, (Germany) – 28th October 2020. Telix has secured an exclusive Intellectual Property licence agreement with the German Cancer Research Center (DKFZ) for a novel imaging technology in the field of image-guided surgery for prostate cancer.

Telix Pharmaceuticals is pleased to announce it has entered into an exclusive Intellectual Property (IP) licence agreement with the German Cancer Research Center (Deutsches Krebsforschungszentrum or ‘DKFZ’) for a novel imaging technology in the field of image-guided surgery for prostate cancer.

The licence agreement is the result of Telix exercising its option under a research collaboration agreement entered into with the DKFZ in August 2019.

This innovative technology involves the use of a ‘dual-labelled’ prostate-specific membrane antigen (PSMA)-targeting molecule that comprises both a radioactive isotope (68Ga) and a fluorescent dye. The resulting imaging agent is able to simultaneously provide both pre-operative imaging of prostate cancer patients with Positron Emission Tomography (PET), as well as highly accurate intra-operative visual (fluorescent) localisation of prostate cancer tissue in real-time by the surgeon.

Telix Pharmaceuticals CEO, Dr. Chris Behrenbruch stated “Robotic surgery delivers over seven million procedures a year globally and already makes extensive use of intra-operative fluorescent imaging. Bringing molecular imaging into the operating theatre is a natural evolution of Telix’s existing commitment to prostate cancer imaging. Our colleagues at the DKFZ have been acknowledged as world leaders in the field of prostate cancer imaging and we are delighted to be further expanding our prostate cancer imaging capability with this excellent technology.”

To read the full ASX release please click here.

TLX591-CDx does not have regulatory approval in any jurisdiction.

More Articles

ASX News

Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 24th November 2020. Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit...

ASX News

Telix Presentation at the European Multidisciplinary Congress on Urological Cancers

20th November 2020 | Corporate Spotlight | Recording of Live Presentation at EMUC20 Virtual Congress: New Perspectives in Prostate and...

ASX News

Telix Receives €545,000 Belgian Research Grant for Prostate Cancer Imaging Agent in Europe

Melbourne (Australia) and Liège (Belgium) – 19th November 2020. Advanced Nuclear Medicine Ingredients S.A. (ANMI) announces a €545,000 payment from...

Corporate Spotlight

Telix presentations at European Association of Nuclear Medicine 2020 Satellite Symposium

13th November 2020 | Corporate Spotlight – Recording of live presentations at EANM Virtual Symposium: Next Generation Imaging with PSMA-PET...

ASX News

Investor Briefing: Telix Pharmaceuticals Limited and China Grand Pharma Partnership

Melbourne (Australia) –  3rd November 2020. Telix Pharmaceuticals Provides Investor Briefing: Our Asian Future

ASX News

Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market

Melbourne (Australia) and Hong Kong SAR (China) – 2nd November 2020. Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic...

ASX News

Activity Report and Sales Note to Accompany Appendix 4C

Melbourne (Australia) – 30th October 2020. Telix Pharmaceuticals provides its Activity Report and Appendix 4C for the quarter ending 30th September 2020,...

Corporate Spotlight

Telix Japan to Present at Japanese Society of Nuclear Medicine Annual Scientific Meeting

28th October 2020 – Clinical Spotlight | Telix Japan to Present at Japanese Society of Nuclear Medicine Annual Scientific Meeting

ASX News

Telix Completes Licence Agreement with German Cancer Research Center (DKFZ) for Image-Guided Prostate Surgery

Melbourne (Australia) and Heidelberg, (Germany) – 28th October 2020. Telix has secured an exclusive Intellectual Property licence agreement with the...

ASX News

Completion of Phase I Enrolment of Japanese Renal Cancer Study

Tokyo (Japan) – 27th October 2020. Telix Pharmaceuticals Japan K.K. is pleased to announce the completion of Phase I enrolment...